Christopher Lanigan
Overview
Explore the profile of Christopher Lanigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dyhdalo K, Ababneh E, Lanigan C, Bowers K, Zhang S, McKenney J, et al.
Int J Gynecol Pathol
. 2023 Feb;
42(5):443-450.
PMID: 36731037
Poorly differentiated malignant neoplasms involving the gynecologic tract routinely include a poorly differentiated endometrial carcinoma (EC) in the differential diagnosis. Some nuclear lineage/site-specific immunohistochemical markers are utilized in this diagnostic...
2.
Bayik D, Lauko A, Roversi G, Serbinowski E, Acevedo-Moreno L, Lanigan C, et al.
Sci Rep
. 2020 Nov;
10(1):18848.
PMID: 33139767
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that are increased in patients with numerous malignancies including viral-derived hepatocellular carcinoma (HCC). Here, we report an elevation of MDSCs in the peripheral...
3.
McHugh K, Mukhopadhyay S, Doxtader E, Lanigan C, Allende D
Am J Clin Pathol
. 2020 Mar;
153(6):811-820.
PMID: 32128564
Objectives: INSM1 has been described as a sensitive and specific neuroendocrine marker. This study aims to compare INSM1 with traditional neuroendocrine markers in gastrointestinal neuroendocrine neoplasms. Methods: Retrospective review (2008-2018)...
4.
Cheah A, Zou Y, Lanigan C, Billings S, Rubin B, Hornick J, et al.
Am J Surg Pathol
. 2018 Jun;
43(1):93-101.
PMID: 29877921
We recently encountered a case of primary pulmonary angiomatoid fibrous histiocytoma (AFH), which was initially misdiagnosed as inflammatory myofibroblastic tumor (IMT) based in part on anaplastic lymphoma kinase (ALK) expression...
5.
Calhoun B, Portier B, Wang Z, Minca E, Budd G, Lanigan C, et al.
BMC Cancer
. 2016 Sep;
16:695.
PMID: 27576528
Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy for breast cancer is associated with improved prognosis in aggressive tumor subtypes, including ERBB2- positive tumors. Recent adoption of pCR as a...
6.
Hembrough T, Liao W, Hartley C, Ma P, Velcheti V, Lanigan C, et al.
Clin Chem
. 2015 Nov;
62(1):252-61.
PMID: 26585927
Background: Crizotinib has antitumor activity in ALK (anaplastic lymphoma receptor tyrosine kinase)-rearranged non-small cell lung cancer (NSCLC). The current diagnostic test for ALK rearrangement is breakapart fluorescence in situ hybridization...
7.
Turakhia S, Lanigan C, Hamadeh F, Swerdlow S, Tubbs R, Cook J
Am J Clin Pathol
. 2015 Jun;
144(1):87-93.
PMID: 26071465
Objectives: Recent reports have used immunohistochemistry (IHC) with a mutation-specific antibody to detect the BRAF V600E mutation, which is found in nearly all cases of hairy cell leukemia (HCL). To...
8.
Minca E, Tubbs R, Portier B, Wang Z, Lanigan C, Aronow M, et al.
Cancer Genet
. 2014 Dec;
207(7-8):306-15.
PMID: 25442074
Cytogenetic alterations are strong outcome prognosticators in uveal melanoma (UVM). Monosomy 3 (-3) and MYC amplification at 8q24 are commonly tested by fluorescence in situ hybridization (FISH). Alternatively, microarray analysis...
9.
Minca E, Wang H, Wang Z, Lanigan C, Billings S, Luo Y, et al.
J Cutan Pathol
. 2014 Nov;
42(2):82-9.
PMID: 25363373
Background: Detection of immunoglobulin light-chain restriction is important in the diagnosis of B-cell non-Hodgkin lymphoma (B-NHL). Flow-cytometry, commonly used to evaluate light-chain restriction, is impractical to be used in cutaneous...
10.
Feng Y, Minca E, Lanigan C, Liu A, Zhang W, Yin L, et al.
J Thorac Oncol
. 2014 Apr;
9(5):646-53.
PMID: 24722154
Introduction: Overexpression of MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) and MET gene amplification have been well-documented in non-small-cell lung cancer (NSCLC). Activated MET signaling plays...